Tor Ole Klemsdal

Dr. Tor Ole Klemsdal

Department of Preventive Cardiology, Oslo University Hospital, 4956 Nydalen N-0424 Oslo, Norway

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in The Lancet
Verified
Journal Article
Closed access
PRPaul M Ridker
Paul M Ridker
JMJean G MacFadyen
Jean G MacFadyen
BEBrendan M Everett
Brendan M Everett
PLPeter Libby
Peter Libby
TTTom Thuren
Tom Thuren
MLMonica Ligueros
Monica Ligueros

1 April 2017 in The Lancet
Verified
Journal Article
Closed access
AAArne Astrup
Arne Astrup
KFKen Fujioka
Ken Fujioka
FGFrank Greenway
Frank Greenway
DLDavid C W Lau
David C W Lau
LGLuc Van Gaal
Luc Van Gaal
JSJames Alan Simon
James Alan Simon

1 October 2010 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
GEGunnar Einvik
Gunnar Einvik
TKTor Ole Klemsdal
Tor Ole Klemsdal
LSLeiv Sandvik
Leiv Sandvik
EHElsa M. Hjerkinn
Elsa M. Hjerkinn
The benefit of n-3 polyunsaturated fatty acids (PUFA) supplementation for mortality and cardiovascular events after myocardial infarction is well documented, but the effect of n-3 PUFA in Caucasians without established cardiovascular disease is not known. Our aim was to examine the influence of supplementation with eicosapentaenoic acid and docosahexaenoic acid on all-cause mortality and cardiovascular events in elderly men at high-risk of cardiovascular disease. In the Diet and Omega-3 Intervention Trial, 563 Norwegian men, 64-76-year old and 72% without overt cardiovascular disease, were randomized to a 3-year 2×2 factorial designed clinical trial of diet counseling and/or 2.4 g n-3 PUFA supplementation. The n-3 PUFA arm was placebo-controlled (corn oil). Demographic parameters and classical risk factors were obtained at baseline. Deaths and cardiovascular events were recorded through 3 years, and the effects of n-3 PUFA-intervention on these outcomes were evaluated in pooled groups of the n-3 PUFA-arm. There were 38 deaths and 68 cardiovascular events. The unadjusted hazard ratios of all-cause mortality and cardiovascular events were 0.57 (95% confidence interval: 0.29-1.10) and 0.86 (0.57-1.38), respectively. Adjusted for baseline age, current smoking, hypertension, body mass index and serum glucose, hazard ratios were 0.53 (0.27-1.04, P=0.063) and 0.89 (0.55-1.45, P=0.641), respectively. We observed a tendency toward reduction in all-cause mortality in the n-3 PUFA groups that, despite a low number of participants, reached borderline statistical significance. The magnitude of risk-reduction suggests that a larger trial should be considered in similar populations.

1 June 2005 in Annals of Emergency Medicine
Verified
Journal Article
Closed access
CKCathrine W. Knudsen
Cathrine W. Knudsen
PCPaul Clopton
Paul Clopton
AWArne Westheim
Arne Westheim
TKTor Ole Klemsdal
Tor Ole Klemsdal
AWAlan H.B. Wu
Alan H.B. Wu
TOTorbjørn Omland
Torbjørn Omland

6 February 2017 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
RSRandi Selmer
Randi Selmer
JIJannicke Igland
Jannicke Igland
IAInger Ariansen
Inger Ariansen
ATAage Tverdal
Aage Tverdal
INInger Njølstad
Inger Njølstad
TKTor Ole Klemsdal
Tor Ole Klemsdal
Guidelines for the prevention of cardiovascular disease recommend the estimation of an individual’s total risk. We have developed a new model for the prediction of the 10-year risk of incident acute myocardial infarction or cerebral stroke based on Norwegian data, NORRISK 2. The model was based on 10-year follow-up of a large population-based cohort (CONOR) through linkage to the CVDNOR project, a database of cardiovascular disease hospital discharge diagnoses and mortality in Norway in 1994–2009. We used the Fine and Gray regression model to estimate the 10-year risk adjusting for competing risk. The model population consisted of participants in 1994–1999 and the external validation population of participants in 2000–2003. We validated the model by area under the receiver operating characteristic curves, calibration plots and analyses of sensitivity and specificity. The model population consisted of 31,445 men and 35,267 women aged 40–79 years with 3658 endpoints in men and 2459 in women. The external validation population consisted of 19,980 men and 19,309 women, of whom 1858 men and 874 women had an endpoint during follow-up. The area under the curve was 0.79 (0.79–0.80) in men and 0.84 (0.83–0.85) in women in the model population and was slightly lower in the external validation population. Calibration plots showed good agreement between observed and predicted risk. The sum of sensitivity and specificity was greatest around the suggested risk thresholds. The NORRISK 2 model showed good validity in an external dataset and will be a valuable tool to guide decisions about preventive interventions in people without known previous cardiovascular disease.

1 March 2010 in Nutrition, Metabolism and Cardiovascular Diseases
Verified
Journal Article
Closed access
TKTor Ole Klemsdal
Tor Ole Klemsdal
IHI. Holme
I. Holme
HNH. Nerland
H. Nerland
TPT.R. Pedersen
T.R. Pedersen
STS. Tonstad
S. Tonstad